I ntracranial "berry" aneurysms are saccular dilatations of an intracranial artery most often located at a branch point of a major artery on the circle of Willis. There is significant evidence that susceptibility to cerebral aneurysms has a significant genetic component. 1, 2 Each year in the United States, Ͼ30 000 people suffer a ruptured intracranial aneurysm that results in a particularly severe form of stroke. Among those individuals who suffer a ruptured intracranial aneurysm, 50% die at the time of rupture or shortly thereafter, and 25% suffer permanent disability, including paralysis and loss of speech, vision, and motor coordination. The remaining 25% are at increased risk of stroke, recurrent bleeding, or other complications. In contrast, operative repair of an unruptured aneurysm has a mortality of Ͻ2.5% and morbidity of Ͻ6%, 3 making treatment during this stage much more palatable. Unruptured aneurysms are a common incidental finding at autopsy and during cerebral angiography and have an estimated prevalence in the general population of 1% to 6%. 3 While the incidence of other types of stroke has declined in recent decades, primarily because of improved detection and management of hypertension, the incidence of subarachnoid hemorrhage has remained relatively constant. Despite the high incidence of intracranial aneurysm and the catastrophic consequences of rupture, relatively little is understood with respect to intracranial aneurysm molecular pathology and pathogenesis. This lack of information has severely hampered efforts to identify individuals at risk of an intracranial aneurysm and to define novel points of therapeutic intervention and is largely due to the difficulty in obtaining suitable aneurysmal tissue specimens for use in these analyses. The few studies that have attempted to investigate the molecular basis of intracranial aneurysm have focused on a limited number of biological markers that have been studied in isolation rather than in a global context. 4, 5 In consequence, previous studies have been significantly biased by a presupposition of intracranial aneurysm pathobiology, and, to our knowledge, no previous semiquantitative comprehensive sampling technique has been applied.
Recent developments in technologies that provide comprehensive, or "global," assays for transcription are yielding detailed information regarding how cell types or whole tissues respond to defined stimuli or define pathological state at the level of transcription. One such approach to defining global transcriptional profiles is Serial Analysis of Gene Expression (SAGE). 6 This is a powerful technique that allows comprehensive analysis of gene expression in a specific cell or tissue type and, unlike hybridization-based approaches using microarrays, 7, 8 is not limited to the analysis of previously identified genes or biased by presumed association between genes of interest and pathobiology. Unfortunately, however, SAGE requires the availability of large quantities of high-quality mRNA, which are not commonly available when studying human disease, particularly intracranial aneurysm. To overcome this, we have recently developed a modification of SAGE that requires only very small (as little as 50 ng) quantities of input total RNA. We call this approach "SAGE-Lite." 9 SAGE-Lite was used in the present study to construct semiquantitative databases of expressed genes in a sample of intracranial aneurysm and superficial temporal artery (STA) obtained from a single individual (internal control). Comparisons made between these databases reveal many genes whose expression is elevated in dilated aneurysmal tissue relative to undilated control STA. This provides a detailed molecular snapshot of intracranial aneurysm and indicates that arterial dilation results in a highly dynamic cellular environment in which high levels of expression of genes previously associated with wound healing and tissue/extracellular matrix (ECM) remodeling take place. We describe the first comprehensive and unbiased semiquantitative analysis of the molecular pathology of an intracranial aneurysm. Although these data are derived from analysis of a single intracranial aneurysm case, this preliminary work identifies candidate genes for use in future biochemical and populationbased genetic studies of aneurysm pathogenesis and rupture.
Materials and Methods

Tissue
A 3-year-old girl presented with a new-onset seizure, and CT scan revealed an intracerebral hemorrhage centered in the sylvian fissure. Angiography demonstrated multiple aneurysms on the distal middle cerebral artery (Figure 1 ). Four days after admission to Presbyterian University Hospital of Pittsburgh, the patient underwent craniotomy for excision of the aneurysmal segment of the middle cerebral artery. Histology confirmed these to be true berry aneurysms and not pseudoaneurysms, as seen with mycotic lesions. Ethical approval for this study was obtained from the institutional review board committee of the University of Pittsburgh.
SAGE-Lite
SAGE-Lite was performed as described previously. 9 Tissue samples were obtained (with institutional review board approval and after informed consent was obtained) in the operating room and snapfrozen on dry ice, and RNA was extracted by the Trizol method (Life Technologies). mRNA was reverse-transcribed (from 100 ng of total RNA) with the use of Superscript II (Life Technologies). First-strand synthesis was primed with a biotinylated oligo(dT) primer (5Ј-AAGCAGTGGTAACAACGCAGAGTACT (30) VN-3Ј (NϭA, G, C, or T; VϭA, G, or C) in the presence of a second oligonucleotide (5Ј-AAGCAGTGGTAACAACGCAGAGTACGCGGG), which acts as a second template during strand switching. 10 First-strand cDNA was amplified with the use of the Advantage cDNA Synthesis System (Clontech) according to the manufacturer's instructions using the same oligonucleotides employed during first-strand synthesis. 9 
Dot Blotting and Hybridization
First-strand cDNA (prepared as described above) was amplified with the use of the Advantage cDNA Synthesis System (Clontech) according to the manufacturer's instructions using a single primer (5-AAGCAGTGGTAACAACGCAGAGT). Amplified cDNA was denatured by heating at 95°C for 10 minutes in a total volume of 500 L and a final concentration of 0.4 mol/L NaOH, 0.1 mol/L EDTA (pH 7.5). cDNAs were then vacuum blotted onto Zeta Probe GT membrane (Bio-Rad), fixed by heating at 80°C for 2 hours, hybridized overnight at 65°C in 0.5 mol/L Na 2 PO 4 and 7% SDS, and washed in 40 mmol/L Na 2 PO 4 and 5% SDS at 65°C.
Statistical Analysis
To prioritize tags for further analysis, we ranked tags in descending order of the importance of the difference between the 2 samples. The importance of the difference was assessed by applying a variancestabilizing transformation to the tag frequencies and then taking the difference between the transformed frequencies in the 2 samples. Because of the exploratory nature of our analysis goals, we did not attempt to develop hypothesis tests to assess the statistical significance of the differences for particular tags. The transformation we used is of the form ln(fϩk), where f is the tag frequency, k is a constant, and ICA indicates intracranial aneurysm, so that the tags are ranked in order of ln(f STA ϩk)Ϫln(f ICA ϩk). The transformation is necessary so that all measurements will have constant variance. It seems clear both from mathematical theory and from experimental data that the raw frequencies have higher variance for larger abundance tags. This means that if the data were ranked on the untransformed differences between the frequencies, high-abundance tags would rise to the top of the list too easily. Similarly, if the data were ranked on the ratio of the frequencies, low-abundance tags would rise to the top of the list too easily. The particular transformation we chose is not necessarily optimal but seems to work well in practice. The value of k used in the transformation is a calibration constant that essentially regulates the relative ease with which highand low-abundance tags can rise to the top of the list. For this data set, we expected a large number of differences between the samples, and therefore we somewhat arbitrarily set kϭ0.001, a value that has performed well over a variety of data sets.
Results
SAGE-Lite Analysis of Gene Expression in Intracranial Aneurysm and STA
SAGE-Lite was used to compare gene expression patterns in a sample of intracranial aneurysm with STA from the same individual, a 3-year-old girl who underwent craniotomy to resect multiple ruptured and unruptured aneurysms in the middle cerebral artery (Figure 1 ). The STA sample was also removed during this procedure.
We sequenced 11 495 and 7297 SAGE tags from the intracranial aneurysm and STA, respectively, and compiled tissue-specific databases of expressed genes. In total, we verified the expression of 4924 and 3552 distinct genes in the intracranial aneurysm and STA samples, respectively. In summary, 31% of the 100 most frequently detected SAGE tags in the intracranial aneurysm are derived from genes that are differentially regulated, with a Ͼ5-fold difference in expression relative to STA. This includes 11 tag species that were undetectable in the STA. Of the top 100 intracranial aneurysm tags, 25% do not match previously characterized gene entries in the GenBank database. Similarly, 29% of the 100 most highly expressed genes in STA are differentially regulated, with a Ͼ5-fold difference in expression relative to intracranial aneurysm. Entire SAGE-Lite data sets are available as publicly accessible, downloadable spreadsheets at www.pitt.edu/‫ف‬dgp. Figure 2A shows the frequencies of each tag (number of times the tag is observed divided by total number of tags sequenced in that sample) in the 2 samples. Figure 2B is an expanded view of the lower-frequency portion of the same plot. Note that most of the lowest-frequency points represent many tags. For example, 2041 tags were observed just once in the STA sample and not at all in the intracranial aneurysm sample. Table 1 is a list of the 25 tags that are overexpressed in intracranial aneurysm and show the most significant differences in abundance between intracranial aneurysm and STA. The list is ranked in order of the differences between the transformed frequencies in the 2 samples (see Materials and Methods).
SAGE-Lite Indicates Extensive Tissue Remodeling in Intracranial Aneurysm
There are a considerable number of genes whose differential expression suggests that the intracranial aneurysm is undergoing significant tissue remodeling (tag counts noted below are shown in parentheses for intracranial aneurysm/STA). For example, a variety of ECM constituents are highly overexpressed in intracranial aneurysm, including the following: fibronectin (443/4), collagen type III ␣-1 (34/7), collagen type I ␣-2 (20/1), collagen type I ␣-1 (17/1 and 16/0), collagen type VI ␣-1 (13/1), collagen type VI ␣-2 (9/1), collagen type IV ␣-1 (5/0), and elastin (5/0).
In addition, numerous other factors known to be involved in ECM turnover and cell migration and adhesion are highly expressed in the intracranial aneurysm. These include tissue inhibitor of metalloproteinase-3 (TIMP-3) (20/0), SPARC (osteonectin) (29/0), "hevin" (6/0), connective tissue growth factor (CTGF) (6/0), ␤-galactosidase-binding lectin (26/7), cdc-rel2a/PNUTL2 (14/0), vinculin (5/1), tetraspanin-5 (5/0), c-Abl (7/0), ␤ig-h3 (6/0); osteoblast-specific factor-2 (OSF-2) (13/0), and cathepsins B (13/1) and D (4/0). Note that observed numbers of gene-specific tags are shown in parentheses (intracranial aneurysm/STA). These data are summarized in Table 2 .
The intracranial aneurysm is also the site of a strong immune/inflammatory response. This is manifested by high levels of expression of mRNAs encoding human leukocyte antigen (HLA) antigens, including HLA-B44 (38/6), HLA-C (16/3), HLA-B (12/1), and ␤2-microglobulin (9/3), which are major histocompatibility complex (MHC) class I markers. The intracranial aneurysm was also found to express HLA-DP4 (8/0), HLA-Dw12 (7/0), and HLA-DR (163/17), which are MHC class II markers, and high levels of mRNAs encoding IgG heavy chain (33/0) and Ig light chain (20/0). The high level of expression of these mRNAs demonstrates a significant inflammatory and/or immune response, which may be associated with infiltrating mononuclear cells and is consistent with intracranial aneurysm undergoing dramatic tissue remodeling. Whether this tissue remodeling is a direct result of aneurysmal dilation and repair or is secondary to the inflammatory response to an intraparenchymal bleed cannot be determined in this limited analysis of one sample.
Confirmation of Differential Gene Expression Patterns in Intracranial Aneurysm
Whole cDNA dot blotting was used to confirm differential gene expression patterns of a subset of genes identified by SAGE-Lite. These data are shown in Figure 3 .
Discussion
We present here the first comprehensive molecular characterization of an intracranial aneurysm and compare its gene expression profile with that of a normal undilated vessel (STA). The use of the STA (an extracranial vessel) as the control vessel, although not ideal, is warranted by the fact that samples were obtained intraoperatively and not obtained postmortem. This approach ensures that RNA samples are freshly harvested and thereby avoids potential problems resulting from excessive RNA degradation that, in our experience, occurs when samples are harvested postmortem. SAGE-Lite indicates an intracranial aneurysm pathology that is highly consistent with tissue injury, wound healing, and extensive ECM remodeling.
To ensure that the cDNA amplification step involved in SAGELite is representative, we have previously performed comprehensive quality control checks to ensure that nonrepresentative amplification is minimal. 9 In addition, the SAGE data contain numerous examples of groups of functionally complementary/overlapping genes that are overexpressed in the intracranial aneurysm at similar magnitudes. Some of these are summarized below, and these further support the accuracy of the data presented. Differential gene expression between intracranial aneurysm and STA was also confirmed for a number of markers using reverse transcriptasepolymerase chain reaction (data not shown). Abundance in intracranial aneurysm (ICA) and STA is shown. Tags/genes are ranked in order of the differences between the transformed frequencies in the 2 samples. Statistical methods used to rank tags are described in Materials and Methods.
By far the most abundantly expressed transcript in the intracranial aneurysm is fibronectin. This was present at much higher levels (approximately 100-fold) in the intracranial aneurysm sample relative to the STA. Fibronectin is a large dimeric glycoprotein found in the ECM of a variety of tissues and is involved in diverse cellular processes, including cell adhesion, cell migration, and repair. High levels of expression of fibronectin in intracranial aneurysm are consistent with a number of previous studies that describe the upregulation of fibronectin as a result of vascular injury 11 and in response to hypertension. 12, 13 Furthermore, it has been suggested that fibronectin organization is altered in experimental cerebral aneurysms in rats. 14 There are also dramatic differences in the levels of a variety of collagen genes expressed in the intracranial aneurysm, and increased aneurysm-specific transcription is observed for TIMP-3. These observations indicate that a high degree of ECM remodeling is taking place in the intracranial aneurysm. This is in general agreement with the previous findings of a number of investigators who have shown that matrix metalloprotease (MMP)-2 and -9 are present at high levels in aneurysmal tissue. 4, 5 We did not detect these MMPs expressed in either the intracranial aneurysm or STA samples, which may indicate that levels of expression of MMPs are low in these particular tissue samples. Consistent with the above observations, a number of other tags representing factors thought to be involved in collagen metabolism are overexpressed in intracranial aneurysm. These include ␤ig-h3 and CTGF. ␤ig-h3 is a cell surface recognition peptide, which is inducible by transforming growth factor-␤ (TGF-␤) and contains a putative binding site (RDG) for integrins. Although the exact function of this factor remains unclear, it may have a bridging function, linking or stabilizing the interactions of collagen with other ECM structures. 15, 16 Similarly, CTGF is a cysteine-rich peptide synthesized and secreted by fibroblastic cells after activation with TGF-␤ that is thought to mediate TGF-␤-induced collagen synthesis. 17 Other highly expressed aneurysm-specific markers include SPARC (osteonectin), which is a counteradhesive glycoprotein expressed in a variety of tissues, including vascular endothelium, smooth muscle, and fibroblasts. SPARC is known to inhibit endothelial cell adhesion and proliferation, and SPARC protein and mRNA have been shown to be increased in renal vascular injury. 19 Indeed, it has been proposed that ECM remodeling is regulated in part by a specific interaction between SPARC and type I collagen. 20 Interestingly, another acidic protein, designated hevin, that is found in the high endothelial venules of lymphoid tissues has antiadhesive properties and is highly related to SPARC. 21 Like SPARC, hevin is expressed in the intracranial aneurysm and is absent in STA.
Other notable intracranial aneurysm-specific mRNAs include cdc-rel2a/PNUTL2, 22 which belongs to an expanding family of GTP binding proteins, called septins, that are thought to be involved in cytokinesis 23 ; vinculin, an adhesion plaque attachment protein; and c-Abl, a nonreceptor tyrosine kinase that is recruited, from the nucleus to focal adhesion sites, by cell adhesion to fibronectin and is thought to phosphorylate the focal adhesion protein paxillin. It is noteworthy that paxillin, an integrin, is a substrate for SPARCinduced tyrosine phosphorylation. 24 Also overexpressed in intracranial aneurysm is ␤-gal-binding lectin (Galectin-1), which is a matricellular protein that has recently been shown to be centrally involved in vascular smooth muscle cell proliferation. 25 There are also a number of factors associated with tissue remodeling whose overexpression in intracranial aneurysm is consistent with ECM remodeling but somewhat less predictable. For example, OSF-2 is a transcription factor that is thought to be restricted to cells of the osteoblast lineage. 26 OSF-2 has been implicated in the activation of collagenase-3 (MMP-13) during bone formation 27 but, to our knowledge, has not been linked to arterial pathologies. Cathepsin B is a lysosomal cysteine protease involved in intracellular protein catabolism and is implicated in cancer 28 and chronic inflammatory diseases of airways and joints. Cathepsin D is an aspartyl endoproteinase that is ubiquitously distributed in lysosomes. 29 In addition to their protein-degrading function in lysosomes and phagosomes, these proteases activate precursors of biologically active proteins in prelysosomal compartments of specialized cells. 30 Cathepsins are clearly implicated in tumor invasion and metastasis through the dissolution of ECM 31, 32 and have been used as prognostic markers for predicting metastatic breast disease. Despite the fact that this characteristic is consistent with tissue remodeling in the vasculature, cathepsins have not been a focus of attention with respect to arterial disorders, although they have recently been associated with the pathogenesis of abdominal aortic aneurysm. 33, 34 The fact that there is a considerable inflammatory/immune component in the intracranial aneurysm is also significant. Whether this is contributing to slow aneurysm growth and expansion or is part of a response to sudden and catastrophic dilation is unknown. It may also be a consequence of an inflammatory reaction, secondary to intraparenchymal hemorrhage after aneurysm rupture. From these preliminary data, derived from a single atypical sample, we are unable to delineate between these possibilities. As such, it will be vital to extend these studies to a wider sample set consisting of more typical examples of both ruptured and unruptured intracranial aneurysms. It will also be important to characterize specific cell types in these aneurysmal biopsies with the use of immunohistochemical techniques to gain a clearer understanding of this aspect of intracranial aneurysm pathology.
In summary, we have characterized, at high resolution, the molecular pathology of an intracranial aneurysm. Although preliminary and based on a single somewhat atypical case, these data are a valuable resource for designing future studies of both the pathology and pathogenesis of intracranial aneurysm in a wider sample set derived from more typical cases. Markers identified in this study may, after further characterization in a wider sample set, become potential targets for noninvasive screening and therapeutic interventions in the management of intracranial aneurysms. Furthermore, the recent results of the International Study of Unruptured Intracranial Aneurysms 35 suggested that aneurysms Ͻ1 cm in diameter carry a very small risk of rupture. This has raised considerable controversy within the neurosurgical community since it is believed that there may be factors other than the size of the lesion that determine risk of rupture. Identifying dynamic aneurysms that are actively undergoing remodeling at a molecular level may prove to be an important determinant of risk of rupture. The same genes may also be regarded as candidates for use in population-based genetic association studies to identify individuals who are at risk of developing an intracranial aneurysm or at increased risk of rupture leading to subarachnoid hemorrhage.
